| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 6 | |
| #2 | Canada | 3 | |
| #3 | Australia | 2 | |
| #4 | EPO (European Patent Office) | 2 | |
| #5 | Republic of Korea | 2 | |
| #6 | China | 1 | |
| #7 | United States | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Medical preparations | |
| #3 | Therapeutic chemical compounds | |
| #4 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Wang Jieyi | 17 |
| #2 | Wu Yi | 16 |
| #3 | Wu Li | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2020231809A1 | Humanized anti-cd137 antibodies and uses thereof | |
| WO2020069382A1 | Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof | |
| WO2020065409A2 | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof | |
| AU2019255781A1 | Anti-CD40 antibodies and uses thereof | |
| WO2019109238A1 | Anti-cd137 antibodies and uses thereof |